CAS:2225856-03-9 , Purity>99%

$1,339.00

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Sku: C-1474-2

Description

Olpasiran is a first-in-class, high-purity small interfering RNA (siRNA) designed to target and inhibit Lipoprotein(a) [Lp(a)] mRNA translation in hepatocytes, thereby reducing plasma Lp(a) concentration. As a precision molecular tool, Olpasiran enables researchers to study the modulation of Lp(a) levels and its impact on cardiovascular risk factors in preclinical and in vitro studies.

Supplied as a solid powder with >99% purity by HPLC, Olpasiran is soluble in DMSO and can be stored at room temperature for several months or at -20°C for long-term storage up to 3 years. This siRNA is an essential reagent for molecular biology, RNA interference, and lipid metabolism research.

Specifications

Product Name Olpasiran
Chemical Formula (Duplex): C490H652F11N164O306P41S7
Molecular Weight 15438.70
CAS# 2225856-03-9
Appearance Solid powder
Purity > 99% by HPLC
Solubility Soluble in DMSO
Storage Room temperature for months, or -20ºC for 3 years

Product information

Targets: Lipoprotein(a); Lipoprotein

Synonym: Olpasiran

Features

  • First-in-Class siRNA: Specifically designed to inhibit LPA mRNA translation in hepatocytes.

  • High Purity: >99% purity by HPLC ensures consistent and reliable experimental results.

  • Targeted Lipoprotein Modulation: Effectively reduces plasma Lipoprotein(a) levels for cardiovascular and lipid research studies.

  • Soluble and Stable: Soluble in DMSO; stable at room temperature for months or at -20°C for long-term storage.

  • Research-Grade Quality: Suitable for molecular biology, RNA interference, and lipid metabolism studies.

Applications

  • Cardiovascular Research: Investigate the role of Lp(a) in atherosclerosis, thrombosis, and lipid metabolism.

  • RNA Interference Studies: Examine gene silencing effects targeting LPA mRNA in hepatocytes.

  • Molecular Biology Research: Study Lp(a)-related pathways and cellular lipid regulation.

  • Drug Development Research: Evaluate potential therapeutics for hyperlipoproteinemia and cardiovascular disorders.

  • Preclinical Studies: Assess functional outcomes of Lp(a) reduction in vitro and ex vivo models.

References

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/8M4GC1EOB4

https://drugs.ncats.io/substance/8M4GC1EOB4

https://pubchem.ncbi.nlm.nih.gov/substance/472420032

Document

Chemical Name/IUPAC

Disclaimer: For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

When can I expect my order to ship?

Most orders are filled and shipped within 2-3 business days from the time they are received.

Our standard shipping usually take 2-5 days.

We also provide express shippping for time-sensitive deliveries. 

Email contact@biofargo.com if you have any requirements.

 

Terms and Conditions